KemPharm, Inc.

    Jurisdiction
    United States
    LEI
    254900CU6T74V18Y1W18
    ISIN
    US4884452065 (KMPH)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €51.13M
    Gross margin
    62.1%
    EBIT
    -€134.96M
    EBIT margin
    -264.0%
    Net income
    -€41.35M
    Net margin
    -80.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €134.50M +163.1% €28.48M -168.9%
    €216.87M +61.2% €105.52M +270.5%
    €290.83M +34.1% €156.01M +47.8%

    Dividends

    No dividend payouts

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Bode John B N/A +5K $9.16 +$45.80K

    Earnings Calls

    Latest earnings call: August 12, 2025

    Add to watchlist

    Notifications